(Image: Associated Press)
Amarin emerges from an expert panel review with a clear endorsement for Vascepa and high odds of success when the FDA weighs in formally
Several FDA experts who gathered Thursday to consider the landmark approval of Vascepa to reduce cardio events in an at-risk population voiced their unease …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
